API015
Total Payments
$27.1M
Transactions
355
Doctors
16
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $4.0M | 77 | 0 |
| 2019 | $13.9M | 98 | 16 |
| 2018 | $8.1M | 94 | 0 |
| 2017 | $1.2M | 86 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.1M | 339 | 100.0% |
| Food and Beverage | $407.20 | 16 | 0.0% |
Payments by Type
Research
$27.1M
339 transactions
General
$407.20
16 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA | Novartis Pharmaceuticals Corporation | $27.1M | 0 |
| A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA | NOVARTIS PHARMACEUTICALS CORPORATION | $700.00 | 0 |
Top Doctors Receiving Payments for API015
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $27.1M | 339 |
| , M.D | Psychiatry | Phoenix, AZ | $25.45 | 1 |
| , M.D | Neurology | Decatur, GA | $25.45 | 1 |
| , M.D., J.D | Neurology | Houston, TX | $25.45 | 1 |
| , MD | Psychiatry | Las Vegas, NV | $25.45 | 1 |
| , M.D | Neurology | Charlottesville, VA | $25.45 | 1 |
| , MD | Family Medicine | Daytona Beach, FL | $25.45 | 1 |
| , MD | Geriatric Medicine | Washington, DC | $25.45 | 1 |
| , M.D | Neurology | Columbus, GA | $25.45 | 1 |
| , M.D | Neurology | New York, NY | $25.45 | 1 |
| , MD | Emergency Medicine | Kissimmee, FL | $25.45 | 1 |
| , MD | Psychiatry | Irvine, CA | $25.45 | 1 |
| , MD | Neurology | Indianapolis, IN | $25.45 | 1 |
| , MD | Neurology | Salt Lake City, UT | $25.45 | 1 |
| , MD,PHD | Neurology | Washington, DC | $25.45 | 1 |
| , MD | Neurology | Providence, RI | $25.45 | 1 |
| , MD | Psychiatry | Sherman Oaks, CA | $25.45 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $27.1M
- Total Doctors 16
- Transactions 355
About API015
API015 is a drug associated with $27.1M in payments to 16 healthcare providers, recorded across 355 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $4.0M was paid across 77 transactions to 0 doctors.
The most common payment nature for API015 is "Unspecified" ($27.1M, 100.0% of total).
API015 is associated with 2 research studies, including "A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA" ($27.1M).